2023

Savoy, L., Long, N., Lee, H., Chen, R., Allen, B., Lin, H. Y., Tognon, C., V. Malhotra, S., Tyner, J. W., & Zhang, H. (2023). CDK12/13 dual inhibitors are potential therapeutics for acute myeloid leukemia. In British Journal of Haematology (Vol. 202, Issue 1). https://doi.org/10.1111/bjh.18843

Basil Allen, Daniel Bottomly, Anthony Wang, Thomas Koehnke, Lindsey Savoy, Peter Ryabini, Reid Chen, Kara Johnson, StephenE. Kurtz, Anupriya Agarwal, Michelle Barton, Brian J. Druker, Ravi Majeti, Jeffrey W Tyner, Shannon K McWeeney, Haijiao Zhang. Cebpβ/IL1/TNFα Positive Feedback Loop Drives Drug Resistance of BCL2 and MDM2 Inhibitors in Monocytic Leukemia Cells. ASH, 2023, San Diego, CA. Blood (2023) 142 (Supplement 1): 2937. https://doi.org/10.1182/blood-2023-178096

2022

Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A, Avaylon S, Benton E, Blucher A, Borate U, Braun TP, Brown J, Bryant J, Burke R, Carlos A, Chang BH, Cho HJ, Christy S, Coblentz C, Cohen AM, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Dibb J, Eide CA, English I, Hagler S, Harrelson H, Henson R, Ho H, Joshi SK, Junio B, Kaempf A, Kosaka Y, Laderas T, Lawhead M, Lee H, Leonard JT, Lin C, Lind EF, Liu SQ, Lo P, Loriaux MM, Luty S, Maxson JE, Macey T, Martinez J, Minnier J, Monteblanco A, Mori M, Morrow Q, Nelson D, Ramsdill J, Rofelty A, Rogers A, Romine KA, Ryabinin P, Saultz JN, Sampson DA, Savage SL, Schuff R, Searles R, Smith RL, Spurgeon SE, Sweeney T, Swords RT, Thapa A, Thiel-Klare K, Traer E, Wagner J, Wilmot B, Wolf J, Wu G, Yates A, Zhang H, Cogle CR, Collins RH, Deininger MW, Hourigan CS, Jordan CT, Lin TL, Martinez ME, Pallapati RR, Pollyea DA, Pomicter AD, Watts JM, Weir SJ, Druker BJ, McWeeney SK, Tyner JW. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022 Aug 8;40(8):850-864.e9. doi: 10.1016/j.ccell.2022.07.002. Epub 2022 Jul 21. PubMed PMID: 35868306; PubMed Central PMCID: PMC9378589. https://pubmed.ncbi.nlm.nih.gov/35868306/

Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K Jr, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022 Feb 21;7(1):51. doi: 10.1038/s41392-021-00870-3. PubMed PMID: 35185150; PubMed Central PMCID: PMC8858957

Lindsey Savoy, Basil Allen, Daniel Bottomly, Reid Chen, Anthony Wang, Hsin-yun Lin, Anupriya Agarwal, Jeffrey Tyner, Shannon Mcweeney, Haijiao Zhang. Characterization of Biomarkers and Mechanisms of Resistance for MDM2 Inhibitors in AML. ASH, 2022, New Orleans, LA. Blood (2022) 140 (Supplement 1): 8778–8779. https://doi.org/10.1182/blood-2022-157622

2020

Zhang H, Nakauchi Y, Köhnke T, Stafford M, Bottomly D, Thomas R, Wilmot B, McWeeney SK, Majeti R, Tyner JW. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020 Aug;1(8):826-839. doi: 10.1038/s43018-020-0103-x. Epub 2020 Aug 18. PubMed PMID: 33123685; PubMed Central PMCID: PMC7591155.

2019

Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood. 2019 Sep 12;134(11):867-879. doi: 10.1182/blood.2019000611. Epub 2019 Jul 31. PubMed PMID: 31366621; PubMed Central PMCID: PMC6742922.

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun.2019 Jan 16;10(1):244. doi: 10.1038/s41467-018-08263-x. PubMed PMID: 30651561; PubMed Central PMCID: PMC6335421.

2018

Zhang H, Paliga A, Hobbs E, Moore S, Olson S, Long N, Dao KT, Tyner JW. Two myeloid leukemia cases with rare FLT3 fusions. Cold Spring Harb Mol Case Stud. 2018 Dec;4(6). doi: 10.1101/mcs.a003079. Print 2018 Dec. PubMed PMID: 30559310; PubMed Central PMCID: PMC6318770.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17. PubMed PMID: 30333627; PubMed Central PMCID: PMC6280667.

Zhang H, Coblentz C, Watanabe-Smith K, Means S, Means J, Maxson JE, Tyner JW. Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation. J Biol Chem. 2018 May 11;293(19):7387-7396. doi: 10.1074/jbc.RA118.002417. Epub 2018 Mar 23. PubMed PMID: 29572350; PubMed Central PMCID: PMC5950016.

2017

Zhang H, Reister Schultz A, Luty S, Rofelty A, Su Y, Means S, Bottomly D, Wilmot B, McWeeney SK, Tyner JW. Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations. Leukemia. 2017 Dec;31(12):2752-2760. doi: 10.1038/leu.2017.126. Epub 2017 Apr 25. PubMed PMID: 28439110; PubMed Central PMCID: PMC5682244.

Zhang H, Means S, Schultz AR, Watanabe-Smith K, Medeiros BC, Bottomly D, Wilmot B, McWeeney SK, Kükenshöner T, Hantschel O, Tyner JW.Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function. Cancer Res. 2017 Aug 15;77(16):4258-4267. doi: 10.1158/0008-5472.CAN-17-1052. Epub 2017 Jun 26. PubMed PMID: 28652245; PubMed Central PMCID: PMC5763920.